论文部分内容阅读
目的:研究红花黄色素注射液对急性非ST段抬高型心肌梗死(NSTEMI)患者血小板聚集率和转化生长因子β1(TGF-β1)的影响,探讨红花黄色素注射液在NSTEMI的作用机制。方法:将65例NSTEMI患者随机分为红花黄色素注射液治疗组(治疗组)和常规治疗组(对照组)。治疗组在常规治疗的基础上静脉点滴红花黄色素注射液,100ml/次,1次/d。检测2组治疗前后血小板聚集率、TGF-β1、高敏C反应蛋白。结果:治疗组血小板聚集率、TGF-β1、高敏C反应蛋白均较对照组显著降低(P<0.05)。结论:红花黄色素注射液可改善NSTE-MI患者的预后,可以作为治疗心肌梗死的辅助药物。
Objective: To investigate the effect of safflower yellow injection on platelet aggregation and transforming growth factor-β1 (TGF-β1) in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) and explore the role of safflor yellow injection in NSTEMI mechanism. Methods: 65 patients with NSTEMI were randomly divided into safflower yellow injection treatment group (treatment group) and conventional treatment group (control group). The treatment group on the basis of conventional treatment, intravenous injection of safflower yellow injection, 100ml / time, 1 time / d. The platelet aggregation rate, TGF-β1 and high-sensitivity C-reactive protein were detected before and after treatment in two groups. Results: The platelet aggregation rate, TGF-β1 and high-sensitivity C-reactive protein in treatment group were significantly lower than those in control group (P <0.05). Conclusion: Safflower yellow injection can improve the prognosis of patients with NSTE-MI and can be used as an adjunct to myocardial infarction.